

Fig. 1




Fig. 2

Inhibition of Jurkat IL-2 Release
by Lovastatin




Fig.3 Inhibition of PBMC IL-2 Release
by Lovastatin




Fig. 4 Inhibition of PBMC TNF- α Release
by Lovastatin




Fig. 5 Inhibition of RBL Cell 5-HT Release by
Lovastatin




Fig.6

Murine Contact Hypersensitivity Model
(Oxazolone)




Fig. 7 Inhibition of IFN γ Release from Jurkat Cells
by Lovastatin and CP129




Fig. 8 Murine Contact Hypersensitivity Model
(DNFB)




Fig. 9 Inhibition of IL-8 Release from Jurkat Cells
by Lovastatin and CP129




Fig. 10 Inhibition of NFAT-Luc Activity in Jurkat Cells
by Fluvastatin Fraction 1079-39 & 1083-7-3




Fig. 11 Inhibition of NFAT-Luc Activity in Jurkat Cells by
Fluvastatin Fraction 8-11




Fig. 12 Effects of CP129 and Fluvastatin Fractions 1079-70, 1079-5, & 1079-1 on NFAT-Luc Activity in Jurkat Stable Cells




Fig. 13 Effect of Various 1079-76 and 1079-77 Fractions on NFAT-Luciferase Activity in Jurkat Cells




Fig. 14 Inhibition of PMA + Thapsigargin-Induced NFAT Activity in Jurkat Cells by 1079-76-3C and -4C




Fig. 15

Inhibition of NFAT Activity in Jurkat Cells
by Fractions 1079-76-3C and -4C




Fig.16 Inhibition of P+I-Stimulated IL-2 Release in Jurkat Cells
by 1079-76-3C and -4C (12401)




Fig. 17




Fig. 18





Fig. 19a

Inhibition of JNK Phosphorylation
by Lovasta

1 2 3 4 5 6

Phospho-p54 JNK →
Phospho-p46 JNK →

p54 JNK →
p46 JNK →



- 1 CONTROL
- 2 LOVASTATIN (20 $\mu\text{g/mL}$)
- 3 ASCOMYCIN (1 ng/mL)
- 4 P + I
- 5 P + I + CP120
- 6 P + I + ASCOMYCIN

Fig. 19b Inhibition of Calcium-Dependent NF-kB
Activity by Lovastatin

